Financials
Financial year 2025
Dr. Philippe DECLERCK, nucleaire geneeskunde from Leuven, company number BE0597858213, closed financial year 2025 with a result of € 138,714 after tax. For that financial year Dr. Philippe DECLERCK, nucleaire geneeskunde recorded a gross margin of € 181,396 and equity of € 161,005. Compared with financial year 2024, the result moved from € 171,479 to € 138,714. The company is profitable. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 23, 2026.
€ 161,005
▼ 18% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 138,714
▼ 19% vs 2024
Profit after tax over the fiscal year.
€ 46,502
▼ 52% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 173,000 paid out
More than the year’s profit went to the shareholders; reserves fell.
People and assets in 2025
0
Average over the fiscal year, from the social balance sheet.
€ 9,127
▼ 35% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 16,822
Loans from banks and other lenders, long and short.
€ 1,797
▲ 58% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 2,492
▼ 93% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 231,614 | € 335,859 | € 229,093 | € 181,396 | ▼ 21% |
| Profit after taxes | € 159,894 | € 236,828 | € 171,479 | € 138,714 | ▼ 19% |
| Equity | € 23,883 | € 23,812 | € 195,291 | € 161,005 | ▼ 18% |
| Total debts | € 211,328 | € 299,226 | € 53,532 | € 21,112 | ▼ 61% |
| Cash | € 46,270 | € 64,981 | € 97,724 | € 46,502 | ▼ 52% |
| Retained profit | € 5,283 | € 5,212 | € 176,691 | € 142,405 | ▼ 19% |
| Dividend | € 159,800 | € 236,900 | € 0 | € 173,000 | |
| Bank debt | € 40,591 | € 27,531 | € 16,904 | € 16,822 | |
| Balance sheet total | € 235,211 | € 323,038 | € 248,823 | € 182,116 | ▼ 27% |
Key figures of Dr. Philippe DECLERCK, nucleaire geneeskunde, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Dr. Philippe DECLERCK, nucleaire geneeskunde?
What happened at Dr. Philippe DECLERCK, nucleaire geneeskunde in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 138,714 (▼ 19% vs 2024). Source: NBB ↗
- New establishment in Leuven. KBO
- ANNE DE ROO became a director. NBB
- PHILIPPE DECLERCK became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 159,894 profit in 2022 to € 138,714 profit in 2025.
Paid € 220,981 in corporate taxes since 2022.
Best year ever: 2023, with € 236,828 profit.
Paid out € 569,700 in dividends to the owners in total.
A new publication or filing at Dr. Philippe DECLERCK, nucleaire geneeskunde? We notify you, reason included.
Follow Dr. Philippe DECLERCK, nucleaire geneeskundeDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind Dr. Philippe DECLERCK, nucleaire geneeskunde are ANNE DE ROO and PHILIPPE DECLERCK.
Directors
According to the 2025 annual accounts
ANNE DE ROO
Director
since 2015
PHILIPPE DECLERCK
Director
since 2015
Establishments
Establishment units
Physical locations of this company
Prosperdreef 20
3001 Leuven
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0597.858.213
- VAT number
- BE 0597.858.213
- Registered office
- Prosperdreef 20, 3001 Leuven
- Names & denominations
- Dr. Philippe DECLERCK, nucleaire geneeskunde
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 10 February 2015
- Peppol
- Active · Active since 27 Mar 2026
- Activities · NACE
Activiteiten van medische beeldvorming en medische laboratoria
Activiteiten van medische laboratoria
Overige dienstverlenende activiteiten op het gebied van informatie
Overige dienstverlenende activiteiten op het gebied van informatie, n.e. g.